NCT02628080View on ClinicalTrials.gov

Atovaquone as Tumour HypOxia Modifier

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Atovaquone

Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.

Trial Locations (1)

OX3 7LE

Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02628080 - Atovaquone as Tumour HypOxia Modifier | Biotech Hunter | Biotech Hunter